VRAX
Virax Biolabs Group Ltd - Class A (VRAX)
Healthcare • NASDAQ • $1.38-4.83%
- Symbol
- VRAX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.38
- Daily Change
- -4.83%
- Market Cap
- $1.95M
- Trailing P/E
- N/A
- Forward P/E
- -0.24
- 52W High
- $21.75
- 52W Low
- $1.38
- Analyst Target
- N/A
- Dividend Yield
- 0.00%
- Beta
- 1.39
Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It …
Company websiteResearch VRAX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.